Nigeria aims to eliminate AIDS by 2030 and has introduced a six-month HIV prevention injection.
Nigeria is introducing long-acting HIV prevention injections, such as Cabotegravir (CAB-LA), to enhance prevention efforts and aims to end the AIDS epidemic by 2030. This initiative aligns with global UNAIDS 95–95–95 targets, aiming to curb high HIV prevalence rates, particularly among key populations. The advent of injectable, long-acting HIV prevention medications, such as Cabotegravir, presents a noteworthy alternative to the daily oral pills, enhancing adherence and lowering transmission rates. Lenacapavir is a long-acting injectable medication for HIV prevention that is administered only twice a year. This initiative is a central part of Nigeria's strategic plan to end HIV/AIDS as a public health threat by 2030. The move is part of the 2030 Agenda for Sustainable Development to end the AIDS epidemic by 2030, a goal supported by PubMed Central (PMC) (.gov). Efforts focus on key populations (female sex workers, men who have sex with men, and injecting drug users) which c...